# EDGAR Filing Document

**Accession Number:** 0000009326
**File Stem:** 0001140361-25-045137
**Filing Date:** 2025-12
**Character Count:** 8114
**Document Hash:** 8da6e5161d1527ec42935a2dddc0cbff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-045137.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001140361-25-045137

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251209

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BALCHEM CORP
- **CENTRAL INDEX KEY:** 0000009326
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 132578432
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13648
- **FILM NUMBER:** 251562198

**BUSINESS ADDRESS:**
- **STREET 1:** 5 PARAGON DRIVE
- **CITY:** MONTVALE
- **STATE:** NJ
- **ZIP:** 07645
- **BUSINESS PHONE:** (845) 326-5600

**MAIL ADDRESS:**
- **STREET 1:** 5 PARAGON DRIVE
- **CITY:** MONTVALE
- **STATE:** NJ
- **ZIP:** 07645

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2025

## Balchem Corporation
(Exact name of registrant as specified in its charter)

Maryland 1-13648 13-2578432 <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

5 Paragon Drive, Montvale, NJ 07645

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (845) 326-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br> Symbol(s) | Name of each exchange on which <br> registered |
| Common Stock, par value $.06-2/3 per share | BCPC | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp; ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐

------

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On December 10, 2025, Balchem Corporation (the "Company") issued a press release announcing a dividend declared by the Company's Board of Directors on December 9, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Further, on December 9, 2025, the Board of Directors of the Company approved a new stock repurchase program which replaces the previous program that was in place and authorizes the repurchase of up to, and including, 4 million shares of the Company's ordinary shares. This new stock repurchase program has no expiration date, does not oblige the Company to acquire any particular amount of the Company's ordinary shares, and may be terminated at any time.

Share repurchases may be made from time to time in the open market, including pursuant to a share repurchase agreement in compliance with Rule 10b-18 or a trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions at the discretion of management.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

<u>Exhibit Number</u> <u>Description</u> <br> [99.1](ef20061036_ex99-1.htm) 104 Press Release dated December 10, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | BALCHEM CORPORATION | BALCHEM CORPORATION |
|  | (Registrant) | (Registrant) |
|  | By: | /s/ Hatsuki Miyata |
|  | Hatsuki Miyata | Hatsuki Miyata |
|  | Executive Vice President, Chief Legal Officer and Secretary | Executive Vice President, Chief Legal Officer and Secretary |
| Date: December 10, 2025 |  |  |

---

------

## Exhibit 99.1

------

#### Exhibit 99.1

#### <br>
![](image00002.jpg)<br>

#### FOR IMMEDIATE RELEASE

#### Balchem Corporation Announces Dividend

**Montvale, New Jersey. December 10, 2025**. Balchem Corporation (NASDAQ: BCPC) today announced that on December 9, 2025, its Board of Directors declared a dividend on its shares of common stock equal to $0.96 per share on the Company's issued and outstanding Common Stock, to be payable on January 20, 2026 to stockholders of record at the close of business on December 23, 2025. This dividend represents an 10.3% increase over last year's annual dividend.

Ted Harris, Balchem's Chairman, President and CEO, said, "Balchem has a longstanding commitment to an annual dividend and we are pleased to announce the continuation of that commitment. This dividend represents the seventeenth consecutive increase in our annual dividend, reflecting both the consistently outstanding financial performance the company has delivered and the Board's continued confidence in our long-term strategies."

#### About Balchem Corporation
Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-ofthe-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market.

#### Forward-Looking Statements
This release contains forward-looking statements, which reflect Balchem's expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem's expectations, including risks and factors identified in Balchem's Annual Report on Form 10-K for the year ended December 31, 2024 and other factors that may be identified in our other SEC filings. Forward-looking statements are qualified in their entirety by the above cautionary 2 statement. Balchem assumes no obligation to update or revise any forward-looking statements as of any future date.

**Contact**:

Jacqueline Yarmolowicz

Balchem Corporation (Telephone: 845-326-5600)

![](image00006.jpg) <br>

------